James Campbell
President & Chief Scientific Officer Centrexion
James Campbell, M.D. is a founder, president and chief scientific officer of Centrexion Therapeutics. Jim is Professor Emeritus of neurosurgery at Johns Hopkins University School of Medicine. He has published over 100 peer-reviewed scientific studies in the field of pain research, which have been recognized through many national honors. In 1996, Jim was president of the American Pain Society. Prior to joining Centrexion, he served as the CEO of Arcion Therapeutics, a biotech company developing topical products for the treatment of neuropathic pain. Earlier in his career, he served as the CEO for Vallinex, Inc. He served as the founder of the American Pain Foundation and was chairman of the board for ten years. He also served as board observer and co-founder of CNS Therapeutics, and was co-founder and on the board of directors of Amplimmune. Jim holds a B.A. in psychology with high honors and high distinction from the University of Michigan, and received his M.D. from Yale University. He received his training in Neurosurgery at the Johns Hopkins Hospital, and is a Diplomate of the American Board of Neurological Surgery.
Seminars
When pain programs fail, it can be difficult to determine whether the underlying biology was flawed or whether efficacy signals were obscured by trial design, patient heterogeneity or inappropriate endpoint selection. This workshop will explore how developers can learn from negative studies, identify responsive patient populations and generate more informative clinical development strategies for future pain therapeutics.
Key Topics Covered:
- How can developers distinguish true target failure from shortcomings in trial design, patient selection or endpoint strategy?
- What impact do patient heterogeneity, comorbidities, concomitant medications and disease duration have on detecting treatment benefit in pain studies?
- What lessons can be learned from programs that failed to meet endpoints, and how might alternative study designs or stratification approaches have altered outcomes?
- How can biomarkers, responder analyses and subgroup identification help uncover hidden efficacy signals and improve future development decisions?
